December 29, 2021 – Quidel Corp. (San Diego, CA) issued a statement from Douglas Bryant, president and CEO of Quidel, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 variants such as Omicron.
“At Quidel, we continuously monitor the evolution and activity of COVID-19 variants in circulation, and the Omicron variant is no exception,” Bryant said. “Recent testing using live South African samples confirmed that our QuickVue® At-Home OTC COVID-19 Test and our Sofia® SARS Antigen FIA are detecting the SARS-CoV-2 Omicron variant.”